Shares of global pharmaceutical company Eli Lilly (NYSE...Data for the week ending April 17 showed that prescriptions for Lilly's injectable weight-loss drug, Zepbound, decreased, while its competitor's drug, Wegovy, saw an increase.
Shares of Eli Lilly came under pressure on Friday after early prescription data for its newly launched weight-loss pill suggested a slower rollout compared with rival Novo Nordisk’s competing product.
The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, and now he can hear,” said one parent ... .
Pfizer challenges Novo and Lilly... Advertisement ... The drug belongs to the popular GLP-1 receptor agonist class, competing with established global giants like Novo Nordisk (Wegovy) and Eli Lilly, as well as local players like Innovent Biologics ... .
Bonhams is offering select items from Diane Keaton’s eclectic collection across four sales this June. Photo by Ruvén Afanador ...Sign Up For Our Daily Newsletter. Sign Up. Thank you for signing up! ... managing director LillyChan said in a statement ... .